The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a significant substantial reduction in body mass and enhance metabolic mar